Wertheimer - The Book of Pharmaceutical & Healthcare Lists

Edited by Albert Wertheimer, Richard Levy and Leo L.H. Lui
i
The Book of Pharmaceutical and Healthcare Lists

Published in 2015 by ILM Publications
Oak Court Business Centre,
Sandridge Park,

Porters Wood,
St Albans,
Hertfordshire,
AL3 6PH, UK

www.ilmpublications.com
Copyright# 2015 ILM Publications
ILM Publications is a trading division of International Labmate Limited

All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any formor by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of theCopyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd,90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the publisher.

Requests to the publisher should be addressed to ILM Publications, Oak Court Business Centre, Sandridge Park,Porters Wood, St Albans, Hertfordshire AL3 6PH, UK, or emailed to info@ilmpublications.com.
Product or corporate names may be trademarks or registered trademarks and are used only for identification andexplanation without intent to infringe. The publisher is not associated with any product or vendor mentioned in this book.

This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted withpermission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publishreliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materialsor for the consequences of their use.

ISBN 978-1-906799-32-8
Printed and bound in the UK by The Manson Group, St Albans, Hertfordshire AL3 6PZCover image Fotolia.com
ii
Table of Contents

About the Editors...............................................................................................................................................................................................viiForeword..............................................................................................................................................................................................................viiiPreface.....................................................................................................................................................................................................................ixAcknowledgements..........................................................................................................................................................................................vii

Pharmaceutical Companies
Table 1.4. Top 20 Global Corporations: Changes in sales from 2007 to 2012 .........................................................................................................5
Table 1.7. PhRMA Companies: Names, Addresses, Phone numbers .......................................................................................................................9

Biotechnology Companies
Table 1.10. Biotechnology Companies Worldwide (BIO members) Generic Drug Companies ..............................................................................12

Mergers and Acquisitions

Employment in U.S. Pharmaceutical and Medicine Manufacturing Industries
Chapter 2. Pharmaceutical Markets and Marketing
Overview................................................................................................................................................................................................................53Global Markets

Table 2.2. Global Pharmaceutical Market by Region, 2012 2017.......................................................................................................................54

U.S Markets

Generic Drug Markets

iii

Promotional Spend
Table 2.24. Professional Detailing Spend, Journal Ad Spending, Professional Meetings Spend, by Company, 2007-2008 .....................................72
Table 2.25. Total Promotional Spend, DTC Spend, E-promotional Spend, by Company, 2007-2008 ......................................................................72

Clinical Trials
Table 3.3. Success Rates for Phase Transition and Clinical Approval Probabilities by Therapeutic Class for
Medicines in Development: Selected Disease Categories
Table 3.5. Medicines in Clinical Trials for Arthritis (2011) ...................................................................................................................................77
New Drug Approvals
Table 3.13. Number of New Therapeutics and Biologics Approvals and Average Approval Times (2001-2011) ...................................................80
Table 3.16. Companies Winning Prix Galien Medals for Pharmaceutical Excellence, 1970 - 2013 .......................................................................81
Table 3.18. Number of New Small Molecule Drug Approvals Per Year Compared to
New Biologic Drug Approvals (1988-2008)..........................................................................................................................................82
Biotechnology Innovation
Table 3.21. Early Biotech and Drug Company Biologics Approvals .......................................................................................................................86
Improvements in Health Outcomes from Pharmaceutical Therapy

Table 4.6. Characteristics of Persons Purchasing Drugs from Mail Order Pharmacies vs. Characteristics
of Persons Purchasing Drugs from Other Outlets, 2005......................................................................................................................105Table 4.8. Percentage of Persons Unable to Receive or Delayed in Receiving Needed Medical Care,
Dental Care, or Prescription Medicines, 2007 .....................................................................................................................................107

Prescription Medications

Healthcare Expenditure

Medicaid/Medicare/Uninsured
Table 5.8. Distribution of Medicaid Enrollees by Enrollment Group by States, Fiscal Year 2010 ......................................................................137
Table 5.9. Distribution of Medicare Beneficiaries by Race/Ethnicity by States, 2010-2011 ...............................................................................138
Table 5.10. People without Health Insurance for the Entire Year, 2008 and 2009 .................................................................................................140
Table 5.11. Medicaid Pharmacy Supplemental Rebate Agreements .....................................................................................................................141
Table 5.12 Medicaid Coverage of Part D Cost Sharing Requirements for Lower-Income Medicare Beneficiaries ............................................142
Table 5.13 Medicaid Managed Care Drug Carve out Data ...............................................................................................................................144
Table 5.14 State Reported Actions Necessary to Implement DRA Medicaid Pharmacy Changes .......................................................................146
Table 5.15 Flexibility Granted by DRA to States to Craft Medicaid Pharmacy Policy .......................................................................................147
Table 5.16 Use of Medicaid Medication Management Programs ........................................................................................................................149